Cart
sales@molnova.com
HPK1-IN-7
CAS No. 2320462-65-3
HPK1-IN-7( —— )
Catalog No. M28709 CAS No. 2320462-65-3
HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 170 | In Stock |
|
| 5MG | 264 | In Stock |
|
| 10MG | 435 | In Stock |
|
| 25MG | 710 | In Stock |
|
| 50MG | 972 | In Stock |
|
| 100MG | 1341 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHPK1-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
In Vitro——
-
In VivoAnimal Model:Mice (MC38 syngeneic tumor model)Dosage:100 mg/kg Administration:Oral; twice daily for 28 days Result:Enhanced the efficacy of anti-PD1 treatment, garnering a 100% cure rate vs a 20% cure rate with anti-PD1 alone.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorEndothelin-1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2320462-65-3
-
Formula Weight458.478
-
Molecular FormulaC24H22N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (272.65 mM)
-
SMILESCC1(C)OC(=O)c2ccc(Nc3ncc(-c4nnco4)c(N[C@H](CO)c4ccccc4)n3)cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kohno M, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241-7
molnova catalog
related products
-
BI-2865
BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively.
-
SSK1
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
-
SC-806
A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM.
